What is the official website of CARVYKTI® ?

The official website of CARVYKTI® is https://www.carvyktihcp.com.

What is CARVYKTI®'s cybersecurity risk score?

CARVYKTI® has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has CARVYKTI® experienced?

According to Rankiteo, CARVYKTI® currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has CARVYKTI® been affected by any supply chain cyber incidents ?

According to Rankiteo, CARVYKTI® has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does CARVYKTI® have SOC 2 Type 1 certification ?

According to Rankiteo, CARVYKTI® is not certified under SOC 2 Type 1.

Does CARVYKTI® have SOC 2 Type 2 certification ?

According to Rankiteo, CARVYKTI® does not hold a SOC 2 Type 2 certification.

Does CARVYKTI® comply with GDPR ?

According to Rankiteo, CARVYKTI® is not listed as GDPR compliant.

Does CARVYKTI® have PCI DSS certification ?

According to Rankiteo, CARVYKTI® does not currently maintain PCI DSS compliance.

Does CARVYKTI® comply with HIPAA ?

According to Rankiteo, CARVYKTI® is not compliant with HIPAA regulations.

Does CARVYKTI® have ISO 27001 certification ?

According to Rankiteo,CARVYKTI® is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does CARVYKTI® operate in ?

CARVYKTI® operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does CARVYKTI® have ?

CARVYKTI® employs approximately None employees people worldwide.

Does CARVYKTI® own any subsidiaries ?

CARVYKTI® presently has no subsidiaries across any sectors.

How many LinkedIn followers does CARVYKTI® have ?

CARVYKTI®'s official LinkedIn profile has approximately 140 followers.

What is the NAICS classification code for CARVYKTI® ?

CARVYKTI® is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does CARVYKTI® have a Crunchbase profile ?

No, CARVYKTI® does not have a profile on Crunchbase.

Does CARVYKTI® have a LinkedIn profile ?

Yes, CARVYKTI® maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/carvykti.

How many cybersecurity incidents has CARVYKTI® experienced ?

As of July 17, 2026, Rankiteo reports that CARVYKTI® has not experienced any cybersecurity incidents.

How many peer or competitor companies does CARVYKTI® have ?

CARVYKTI® has an estimated 5,710 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

CARVYKTI®

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

CARVYKTI® Vendor Cyber Rating & Cyber Score

carvyktihcp.com

Add Your Compliance Badge

Please see Important Safety Information in the pinned post below and at https://www.carvyktihcp.com/#isi. This product information is intended for US healthcare professionals only. CARVYKTI® is a product of Johnson & Johnson and Legend Biotech and is not associated with any individual users on LinkedIn. Please read full Prescribing Information, including Boxed Warning, for CARVYKTI® at https://www.carvyktihcp.com/pi © Johnson & Johnson and its affiliates 2025 © Legend Biotech USA Inc. 2025 All rights reserved. 06/25 cp-501818v1

CARVYKTI® A.I CyberSecurity Scoring

Scoring History

CARVYKTI®

CARVYKTI® CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

CARVYKTI® Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for CARVYKTI®

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for CARVYKTI® in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for CARVYKTI® in 2026.

Incident Types CARVYKTI® vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for CARVYKTI® in 2026.

Incident History - CARVYKTI® (X = Date, Y = Severity)

Loading…

SUBSIDIARY

CARVYKTI® Subsidiaries

Parent Company

CARVYKTI®

Pharmaceutical Manufacturing

Website: https://www.carvyktihcp.com

Company Size: None employees

No subsidiary data available for this company.

Loading…

CARVYKTI® Similar Companies

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Loading…

NEWS

CARVYKTI® CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-44453

SUMMARY

h2o is an HTTP server with support for HTTP/1.x, HTTP/2 and HTTP/3. Prior to commit 6b5370d, h2o is vulnerable to a Denial of Service attack when calling alloca under certain conditions. When serving static files, h2o builds the file path on stack, by calling alloca. The maximum size of the memory allocated using alloca can be as huge as ~600KB, which exceeds the default pthread stack size used by musl libc (128KB). If the amount of memory allocated by alloca exceeds the stack size, the h2o server crashes with a segmentation fault, while it tries to touch the guard page. This issue has been fixed by commit 6b5370d.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-44452

SUMMARY

h2o is an HTTP server with support for HTTP/1.x, HTTP/2 and HTTP/3. Prior to commit 8dc37cb, when h2o receives a ClientHello message over TLS or QUIC and it contains a zero-length SNI extension, the h2o server runs over the zero-length hostname while trying to copy the hostname, assuming that it is NULL-terminated. This is a potential denial-of-service attack vector in sense that it might trigger segmentation violation. This issue has been fixed by commit 8dc37cb.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-44436

SUMMARY

Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit 8b178e6, Quicly is vulnerable to a Denial of Service attack through connection state corruption. In QUIC Invariants, the maximum length of a Connection ID is 255 bytes, while QUIC version 1 further restricts the maximum to 20 bytes. Quicly implements QUIC version 1 and therefore its CID buffers are limited to 20 bytes. However, to be able to respond to unknown versions of QUIC, its packet decoder accepts Connection IDs of up to 255 bytes. As its CID buffers are merely 20 bytes long, Quicly must reject QUIC version 1 packets with Connection IDs longer than that. The command line tool bundled with Quicly has had that check, however the library itself lacked such enforcement. As a consequence, when used by applications that lack their own enforcement, the connection state becoming inconsistent to buffer overrun. Fortunately, the overflow stops within the allocated chunk of memory, but nevertheless, the bug leads to assertion failures. This issue has been fixed by commit 8b178e6.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-44435

SUMMARY

Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit 937d0e9, an assertion failure is raised when the total number of valid handshake messages received over a CRYPTO stream of a single packet number space exceeds 32KB, causing a Denial of Service. This issue has been fixed by commit 937d0e9.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-44434

SUMMARY

Quicly is an IETF QUIC protocol implementation intended primarily for use within the H2O HTTP server. Prior to commit dccf5d4, Quicly was vulnerable to stateless reset injection through lack of packet entry validation. The QUIC protocol is designed to withstand packet injection attacks, once the handshake is complete. Only packets that carry some secret patterns are considered as stateless resets. Quicly allows the peer to share up to 4 such patterns per connection. However, until now, it failed to determine which of the 4 slots that it uses to retain the secret patterns contains a valid entry. As the slots are zero-initialized, the failure meant that, unless the peer advertised 4 of such patterns, an all-zero pattern was treated as a stateless reset.In effect, this allowed an on-path attacker to reset QUIC connections governed by Quicly. This issue has been fixed by commit dccf5d4.

Published

Date2026-07-16

Updated

Date2026-07-16

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…